Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cingulate Inc. - Common Stock (NQ:CING)

5.950 -0.250 (-4.03%)
Streaming Delayed Price Updated: 3:58 PM EDT, Apr 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cingulate Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Why Avantax Shares Are Trading Higher By Over 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) jumped 76% to $28.13 after the company's once-daily oral paltusotine achieved the primary and secondary endpoints in the Phase 3 PATHFNDR-1 study... 
Via Benzinga
News headline image
ADHD-Focused Cingulate Prices Public Offering, Shares Detailed Pivotal Trial Data ↗
Cingulate Inc (NASDAQ: CING) shares are trading lower after the company priced its $4-million public offering at around 58 cents per share  
Via Benzinga
News headline image
Why Tenon Medical Shares Are Trading Lower By 34%; Here Are 20 Stocks Moving Premarket ↗
Gainers 
Via Benzinga
News headline image
Why Are Cingulate Shares Trading Higher Today? ↗
Cingulate Inc (NASDAQ: CING) announced topline results from its Phase 3 adult trial of its lead candidate, CTx-1301 (dexmethylphenidate) for attention-deficit/ 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Why Mitek Systems Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket ↗
Gainers Marin Software Incorporated (NASDAQ: MRIN) rose 32.8% to $0.5698 in pre-market trading after the company reported HubSpot integration. 
Via Benzinga
News headline image
Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023
Data Accepted as Finalist for First Annual Poster Awards 
From Cingulate Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
From Cingulate Inc.
Via GlobeNewswire
News headline image
Why Celestica Shares Are Trading Higher By Over 42%; Here Are 20 Stocks Moving Premarket ↗
Gainers Celestica Inc. (NYSE: CLS) shares surged 42.2% to $23.40 in pre-market trading after the company announced better-than-expected second-quarter results. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  On Tuesday, 56 companies set new 52-week lows. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Why Lucid Group Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Healthcare Triangle, Inc. (NASDAQ: HCTI) shares climbed 171.2% to $8.84 as the company launched initiative to prevent ransomware attacks in the $35 billion healthcare data market. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why ImmuCell Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗
Gainers Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) shares surged 131.6% to $4.03 in pre-market trading after gaining 15% on Tuesday. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
It's time to start off Wednesday with an overview of all the biggest pre-market stock movers worth watching this morning! 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
Results Indicative that CTx-1301 Provides Entire Active-Day Efficacy with Optimal Onset and Duration 
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August
Announcement Confirms Cingulate on Track with Development and Regulatory Milestones 
From Cingulate Inc.
Via GlobeNewswire
News headline image
Why Surgalign Holdings Shares Are Trading Lower By Around 75%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Airspan Networks Holdings Inc. (NYSE: MIMO) shares gained 79.5% to $0.2740. 
Via Benzinga
News headline image
Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate to Present at 13th Annual LD Micro Invitational
From Cingulate Inc.
Via GlobeNewswire
News headline image
Partnership By Biotech Firm Could Be Big News For The Commercialization Of Its Innovative ADHD Drug Candidate ↗
Shane Schaffer, Chairman & CEO of Cingulate (NASDAQ: CING), and Tim Moore, Senior VP of Biotech of Indegene, were recently guests on Benzinga’s All Access. 
Via Benzinga
News headline image
Cingulate, Indegene to Participate in Benzinga All Live Access Event
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate Announces Successful Transfer of CTx-1301 (dexmethylphenidate) Proprietary PTR™ Manufacturing Processes to Societal CDMO
Scalable Supply of CTx-1301 Ready to be Produced with Cingulate on Track to Meet Previously Announced Clinical Timelines for Phase 3 Trial Program 
From Cingulate Inc.
Via GlobeNewswire
News headline image
Cingulate: This Novel Drug Technology May Soon Relieve A Patient's "Pill-Burden" ↗
Shane Schaffer, Chairman & CEO of Cingulate (NASDAQ: CING), was recently a guest on Benzinga’s All-Access. 
Via Benzinga
News headline image
Cingulate to Participate in Benzinga All Live Access Event
From Cingulate Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.